Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nihon Pharma Failed To Inform Patients About Factor IX Administration

This article was originally published in PharmAsia News

Executive Summary

Nihon Pharmaceutical, manufacturer of Factor IX product PPSB-Nichiyaku, announced that it withheld information on two patients who were administered the product and later affected by hepatitis C. The company received the information from a medical facility around 1979 and failed to notify the patients. Earlier this month, after it received an order from Japan's Ministry of Health, Labor and Welfare, Nippon Pharma started looking for the two patients; however, since the medical facility did not keep their records, the specific persons have yet to be notified. Nippon Pharma has expressed regret about the incident and called for concerned parties to step forward. Nippon Pharma is the second pharmaceutical company admitting to have kept such information secret, after Mitsubishi Tanabe acknowledged it failed to notify patients regarding Fibrinogen. (Click here for more-Japanese language

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068069

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel